BridgeMD
Transfer of prednisolone into human breast milk and plasma of breastfeeding children
EU CTIS ID: 2023-508913-18-00
What this study is testing
The primary objective is to determine the concentration of prednisolone in the plasma of breast-fed infants of lactating women treated with prednisolone to reduce inflammation in a variety of conditions.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Breastfeeding women treated with prednisolone with doses up to 50mg/day for any condition and her child.
- Only women of 18 years of age and older will be asked for participation.
- Signed Informed consent form from the woman that participates in the study and the father of the child.
You likely can't join if
- Woman not able to read and communicate in Swedish or English.
- Women with infant born prior to 37 weeks gestation (premature).
- Women with multiple births.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.